Company Filing History:
Years Active: 2011
Title: The Innovative Contributions of Inventor Stefan Gussregen
Introduction
Stefan Gussregen, a talented inventor based in Wiesbaden, Germany, has made significant strides in the field of pharmaceuticals. With two patents to his name, his work primarily focuses on compounds that have the potential to treat diseases related to enzyme regulation.
Latest Patents
Stefan’s latest inventions include two notable patents:
1. **Substituted Quinoxalines**: This invention relates to a compound of formula (I), which has therapeutic use as 11β-HSD1 modulators. It encompasses the preparation and pharmaceutical composition of these compounds, highlighting their applications in treating diseases linked to the enzyme 11β-HSD1.
2. **Urea Derivatives of Tropane**: This patent emphasizes a compound of formula (I) as well, focusing on its preparation and therapeutic application as a modulator of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). This work aims to contribute to innovative treatments for conditions influenced by this enzyme.
Career Highlights
Stefan Gussregen works at Sanofi-Aventis, a prominent company in the pharmaceutical sector. His role involves conducting research and development that leads to impactful medical solutions, underscoring his commitment to advancing healthcare through innovation.
Collaborations
Throughout his career, Stefan has collaborated with esteemed colleagues such as Michel Aletru and Alain Jean Braun. These partnerships reflect his dedication to fostering teamwork and leveraging collective expertise to drive successful outcomes in pharmaceutical innovation.
Conclusion
Stefan Gussregen’s journey as an inventor showcases the importance of innovative thinking in the pharmaceutical industry. His groundbreaking patents not only highlight his individual contributions but also serve as a testament to the collaborative efforts within Sanofi-Aventis, aiming for advancements in healthcare that benefit society as a whole.